British Biotech ends takeover talks with German rival
Thursday 24 October 2002
British Biotech, the one-time star of the UK biotech industry, has failed in its latest attempt to pull off a big takeover.
It called off talks with the German biotech company MorphoSys after shareholders and analysts argued it had picked the wrong potential partner.
Elliot Goldstein, the Canadian chief executive brought in four years ago to turn British Biotech's fortunes around, said he would continue hunting for a new deal to make use of the company's £47m cash pile.
There is no prospect of any of British Biotech's remaining in-house drugs reaching the market before the cash runs out.
Mr Goldstein said the British Biotech board called off merger talks on Tuesday. "This is the sort of thing that happens all the time, just normally it happens behind closed doors. We had to announce it because the talks had leaked out but, having laid down a certain number of objectives for creating shareholder value, yesterday we came to the conclusion that it wasn't going to meet them."
Mr Goldstein was at pains to say the deal did not fall down as a result of disagreements over management structure. Previous merger talks with cancer specialists including Antisoma and Xenova are widely believed to have failed after disagreements over Mr Goldstein's own future role. He said the merger with MorphoSys would have given him an ongoing role with the company, and that the management structure had been agreed early in the talks.
British Biotech shares have halved since the company admitted talks early last month, and were down 0.1p to 2.55p yesterday. The deal was roundly criticised because it would not satisfy British Biotech's perceived urgent need for cash-generating products. MorphoSys has the technology to start drug development work, but no products in human trials.
Observers said the technology and the early stage products it had generated had not impressed the British Biotech team doing due diligence work.
Mr Goldstein said the breakdown of exclusive talks with MorphoSys freed him up to talk to other potential partners, but analysts were sceptical he could agree a deal.
Exclusive: World’s most pristine waters are polluted by US Navy human waste
Chicago river turns green to mark Saint Patrick's Day
Saint Patrick's Day: As Google Doodle celebrates the patron saint of Ireland, here are 10 things you didn't know about the man himself
Missing Malaysia Airlines Flight MH370: Did jetliner fly into area controlled by Taliban? Net widens after claims final satellite signal could have been sent from the ground
Nasa-funded study warns of ‘collapse of civilisation’ in coming decades
Katie Hopkins continues campaign to become Britain's most hated talking head with poorly timed Bob Crow tweet
Ukip and Nigel Farage on course for remarkable victory in European elections
No EU referendum under Labour: Ed Miliband to reveal that vote on membership is ‘unlikely’ in next Parliament if party wins power
Tony Benn was entirely ineffectual - and usually wrong
The rise of Ukip: Study warns Labour that Eurosceptic party's electoral base now 'more working class than any of the main parties'
Europeans have ‘got whiter’ due to natural selection in past 5,000 years, scientists say
- 1 Is your name now 'banned' in Saudi Arabia?
- 4 Nasa-funded study warns of ‘collapse of civilisation’ in coming decades
iJobs Money & Business
£35000 - £43000 per annum + Bonus and Benefits: Harrington Starr: A global lea...
£50000 - £60000 per annum: Harrington Starr: Linux Systems Administrator - UNI...
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£37000 - £40000 per annum + £20000 benefits package: Pro-Recruitment Group: **...